Independent of PPAR-γ regulation the modification of FABP4 function by specific antagonists, inhibitors of gene expression (for example microRNA), or neutralizing antibodies could be novel therapeutic approaches for treating diseases such as obesity, DM, cardiovascular disease, and atherosclerosis. This evidence concerns the gene PPARG and diabetes mellitus.